Design and Characterization of Atenolol Transdermal Therapeutic Systems: Enhancement of Permeability via Iontophoresis

References

1. 1.↵
   1. Barry B. W

   . Is transdermal drug delivery research still important today? Drug Discov. Today 2001, 6 (19), 967–971.

   OpenUrlPubMed
2. 2.↵
   1. Al-Khalili M.,
   2. Meidan V. M.,
   3. Michniak B. B

   . Iontophoretic transdermal delivery of buspirone hydrochloride in hairless mouse skin. AAPS PharmSciTech 2003, 5 (2), 1–11.

   OpenUrl
3. 3.↵
   1. Gannu R.,
   2. Yamsani V. V.,
   3. Palem C. R.,
   4. Yamsani S. K.,
   5. Yamsani M. R

   . Iontophoretic delivery of lisinopril: optimization of process variables by Box-Behnken statistical design. Pharmaceutical Development and Technology 2010, 15 (2), 169–177.

   OpenUrlPubMed
4. 4.↵
   1. Esteves de Castro R. A.,
   2. Canotilho J.,
   3. Barbosa R. M

   . Infrared spectroscopy of racemic and enantiomeric forms of Atenolol. Spectrochimica Acta A Mol. Biomol. Spectrosc. 2007, 67 (5), 1194–1200.

   OpenUrl
5. 5.↵
   1. Gondaliya D.,
   2. Pundarikakshudu K

   . Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion. AAPS PharmSciTech 2003, 4 (1), 1–9.

   OpenUrl
6. 6.↵
   1. Murthy S. N.,
   2. Hiremath S. R. R

   . Physical and chemical permeation enhancers in transdermal delivery of terbutaline sulfate. AAPS Pharm SciTech 2001, 2 (1), 1–5.

   OpenUrl
7. 7.↵
   1. Brand R. M.,
   2. Iversen P. L

   . Iontophoretic delivery of a telomeric digonucleotide. Pharm. Res. 1996, 13, 851–854.

   OpenUrlPubMed
8. 8.↵
   1. Bhaskara B. L.,
   2. Kumar S. A.,
   3. Kumar U. R. A

   . A facile and rapid HPLC method for the determination of atenolol in pharmaceutical formulations. Asian J. Appl. Sci. 2011, 4, 306–313.

   OpenUrl
9. 9.↵
   1. Eaga C. M.,
   2. Somagoni J. M.,
   3. Maddi S. R.,
   4. Reddy S.,
   5. Yamsani M. R

   . New chiral reverse phase HPLC method for determination of atenolol enantiomers in pharmaceutical formulations. International Journal of Pharmaceutical Sciences Review and Research 2010, 4 (1), 22–26.

   OpenUrl
10. 10.↵
    1. Prausnitz M. R.,
    2. Lee C. S.,
    3. Liu C. H.,
    4. Pang J. C.,
    5. Singh T.,
    6. Langer R.,
    7. Weaver J. C

    . Transdermal transport efficiency during skin electroporation and iontophoresis. J. Controlled Release 1996, 38, 205–217.

    OpenUrlCrossRef
11. 11.↵
    1. Anroop B.,
    2. Ghosh B.,
    3. Parcha V.,
    4. Khanam J

    . Transdermal delivery of atenolol: effect of prodrugs and iontophoresis. Current Drug Delivery 2009, 6 (3), 280–290.

    OpenUrlPubMed
12. 12.↵
    1. Inal O.,
    2. Kiliçarslan M.,
    3. Ari N.,
    4. Baykara T

    . In vitro and in vivo transdermal studies of atenolol using iontophoresis. Acta Pol. Pharm. 2008, 65 (1), 29–36.

    OpenUrlPubMed
13. 13.↵
    1. Patel N. B.,
    2. Sonpal R. N.,
    3. Mohan S.,
    4. Selvaraj S

    . Formulation and evaluation of iontophoretic transdermal delivery of diltiazem hydrochloride. Int. J. Res. Pharm. Sci. 2010, 1 (3), 338–344.

    OpenUrl
14. 14.↵
    1. Wang H.,
    2. Hou H.-M

    . Improvement of transdermal permeation of captopril by iontophoresis. Acta Pharmacol. Sin. 2000, 21 (7), 591–595.

    OpenUrlPubMed